Biotech Stocks Diverge Amid Patent News and Clinical Setbacks
1 report, 1 independent
Updated Sep 1
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
ENCell Co.,Ltd. and VUNO Inc. posted double-digit gains following patent and research news. Separately, Bristol-Myers Squibb discontinued clinical development of ORM-6151, an acute myeloid leukemia candidate it acquired from Orum Therapeutics, Inc. The drug used Orum's degrader-antibody conjugate technology.
From edaily.co.kr
Why it matters
The clinical setback by Bristol-Myers Squibb raises uncertainty regarding the clinical proof of concept for Orum's core technology. The market reaction showed a sharp divergence among South Korean biotech stocks.
From edaily.co.kr
Who's involved
- Bristol-Myers SquibbAmerican pharmaceutical company that discontinued clinical development of ORM-6151
- Samsung Life Public Welfare FoundationOrganization whose work was involved in a U.S. patent secured by ENCell
Keep exploring
The entities involved
-
Bristol-Myers Squibb
American pharmaceutical company